OncLive TV

Patrick Y. Wen, MD, discusses the efficacy of the pan-RAF inhibitor tovorafenib in children and young adults with low-grade glioma and highlights the importance of continual clinical research in this disease.

Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Catherine Ann Shu, MD, discusses key therapeutic advances in the adjuvant setting for patients with early-stage non–small cell lung cancer.

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.

Stefan Maksimovic, MD, discusses the preclinical investigation of innovative tissue engineering with optical windows, state-of-the-art fluorescence reporter technology, and intravital multiphoton microscopy in mouse models with clear cell renal cell carcinoma.

Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.

Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.

Christine Bestvina, MD, discusses strategies for managing adverse effects associated with the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.

Amer Zeidan, MBBS, discusses classification and treatment updates for patients with myelodysplastic syndrome.

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.

Erica L. Mayer, MD, MPH, discusses findings from research investigating CDK4/6 inhibitors in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.

Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.

Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.

Benjamin Philip Levy, MD, discusses the evolution of antibody-drug conjugates in non-small cell lung cancer following updated data to be read out for this treatment population throughout 2023.

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

David R. Wise, MD, PhD, discusses the importance of germline and somatic testing in patients with metastatic castration-resistant prostate cancer, and the need for improved testing practices in clinical practice.

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.

Marc J. Braunstein, MD, PhD, discusses the evolution of autologous stem cell transplantation and ongoing treatment needed to better determine when ASCT should be recommended for patients with multiple myeloma.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the rationale for launching the phase 3 IMCgp100-202 trial evaluating tebentafus in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, as well as the mechanism of action of the agent.

Jason Porter, MD, discusses the potential role of the next-generation TKI taletrectinib in patients with ROS1-positive non–small cell lung cancer, according to data from the phase 2 TRUST-II trial.

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Arpita Desai, MD, discusses the impact that the findings from the phase 3 CONTACT-03 trial had in patients with metastatic renal cell carcinoma.